151. The atypical IκB family member Bcl3 determines differentiation and fate of intestinal RORγt+regulatory T-cell subsets
- Author
-
Köhler, Amelie, Geiselhöringer, Anna-Lena, Kolland, Daphne, Kreft, Luisa, Wichmann, Nina, Hils, Miriam, Pasztoi, Maria, Zurkowski, Elena, Vogt, Johannes, Kübelbeck, Tanja, Biedermann, Tilo, Schmitz, Ingo, Hansen, Wiebke, Kramer, Daniela, Gaida, Matthias M., Schmidt-Weber, Carsten B., Hoevelmeyer, Nadine, and Ohnmacht, Caspar
- Abstract
Peripherally-induced regulatory T cells (pTregs) expressing the retinoic acid receptor-related orphan-receptor gamma t (RORγt) are indispensable for intestinal immune homeostasis. Nuclear factor kappa family members regulate the differentiation of thymic Tregs and promote their survival in the periphery. However, the Treg intrinsic molecular mechanisms controlling the size of the pTregs in the intestine and associated lymphoid organs remain unclear. Here, we provide direct evidence that B-cell lymphoma 3 (Bcl3) limits the development of pTregs in a T cell-intrinsic manner. Moreover, the absence of Bcl3 allowed for the formation of an unusual intestinal Treg population co-expressing the transcription factors Helios and RORγt. The expanded RORγt+Treg populations in the absence of Bcl3 displayed an activated phenotype and secreted high levels of the anti-inflammatory cytokines interleukin (IL)-10 and transforming growth factor beta. They were fully capable of suppressing effector T cells in a transfer colitis model despite an intrinsic bias to trans-differentiate toward T helper 17-like cells. Finally, we provide a Bcl3-dependent gene signature in pTregs including altered responsiveness to the cytokines IL-2, IL-6, and tumor necrosis factor alpha. Our results demonstrate that Bcl3 acts as a molecular switch to limit the expansion of different intestinal Treg subsets and may thus serve as a novel therapeutic target for inflammatory bowel disease by restoring intestinal immune tolerance.
- Published
- 2024
- Full Text
- View/download PDF